Healthy Volunteers Clinical Trial
— BEOfficial title:
An Open Label, Randomized, Single Dose, Two-way Crossover , Two-Period, Two-Treatment, Two-Sequence Bioequivalence Study of Klaribact Tablet (Clarithromycin 500 mg), Compared With Reference Product, Klaricid Tablet (Clarithromycin 500 mg) in Healthy Adult Male Subjects
Verified date | September 2022 |
Source | University of Karachi |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is An Open Label, Randomized, Single Dose, Two Way Cross over, Two Period, Two Treatment, Two Sequence Bioequivalence Study to compare the rate and extent of absorption of Klaribact FC Tablet (Clarithromycin 500 mg) with Reference Product, Klaricid FC Tablet (Clarithromycin 500 mg) in healthy adult male subjects under fasting condition.
Status | Completed |
Enrollment | 24 |
Est. completion date | December 25, 2012 |
Est. primary completion date | November 2, 2012 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Male |
Age group | 18 Years to 50 Years |
Eligibility | Inclusion Criteria: - All subjects should be healthy and free from any epidemic, contagious or measurable disease (e.g. Malaria, Dengue). - Age range for inclusion will be 18-50 year. - BMI for all Subjects will be between 18.5-26.9 kg/m2. - Participant capable of understanding the informed consent. - Non Smokers, who have not smoked in last 3 months. - Medical history, physical examination and screening tests must fall in normal range, unless the investigator considers the abnormality to be clinically not significant. - Clinical laboratory test results should be within a normal range. - Participants (who can read and understand urdu) should be able to give informed consent, understand and sign the Informed Consent Form. - Participants should have adequate organ function (i.e., kidney, liver and heart). - Subjects with negative urine screen for drugs of abuse. All subjects will have urine samples assayed for the presence of drugs of abuse as part of the clinical screening procedures and at each study period check-In. Exclusion Criteria: - Any active allergic disease or a history of any significant allergic disease (e.g. Rhinitis, dermatitis, asthma). - Known hypersensitivity to Investigational drug(s). - Abnormal results of blood and urine tests conducted at screening unless the investigator considers an abnormality to be clinically irrelevant. - Presence or history of cardiac (e.g. Myocardial Infarction, arrythmia), renal (e.g.renal insufficiency) , hepatic (e.g. hepatic impairment) , organ insufficiency, bone marrow disease, hematological abnormality (e.g. leukemia, anemia),photosensitivity, neurological disorders (e.g. Alzheimer's disease) or gastrointestinal disease known to interfere with the drug absorption, distribution, metabolism or elimination (e.g. dysphagia). - History or presence of any musculo skeletal disease (e.g. Tendonitis). - Subject donated blood (450ml) within 12 weeks minimum preceding the study. 19 - Alcoholic or with a history of chronic alcohol intake or consumed alcohol or Gutka in last 3 months. - Ingestion of OTC drug, within 14 days of drug administration (e.g. aspirin, ibuprofen). - History of intake of any prescribed medicine (e.g. captopril, sumatriptan) during a period of 30 days, prior to drug administration day of study. - Ingestion of investigational drug within 30 days, prior to investigational drug administration in the study. - Ingestion of any known hepatic or renal clearance altering agents (e.g. erythromycin, cimetidine, barbiturates, phenothiazines, etc.) for a period of 30 days, prior to study initiation. Drug interaction section at 5.12 should be considered. - Subjects with an uncontrolled medical condition (i.e., hypertension, cardiac arrhythmias, CHF) that places the patient at risk by participating in the study. - Subjects with known HIV, hepatitis B or C infection or autoimmune diseases. - History of drug exposure which, in the opinion of Investigator, amounts to drug abuse. - Participation in other drug studies within three months prior to study initiation. - Subjects with any physical/mental disability. - Limited mental capacity to the extent that the subject is unable to provide legal consent and information regarding the side effects or tolerance of the study drug. - Pregnancy or breast feeding, women of child bearing age who are not using a recognized form of contraception for at least last 30 days or using hormonal contraception, are also excluded. |
Country | Name | City | State |
---|---|---|---|
Pakistan | Center for Bioequivalence Studies and clinical research (CBSCR), ICCBS | Karachi | Sindh |
Lead Sponsor | Collaborator |
---|---|
University of Karachi | Center for Bioequivalence Studies and Clinical Research, Merck Pvt. Ltd, Pakistan |
Pakistan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | maximum plasma drug concentration | maximum drug concentration in plasma after dosing | up to 24 hours post dose | |
Primary | AUC last (AUC 0-t) | Area under plasma concentration time curve from zero to time of the last measurable concentration | 0 to 24 hours post dose | |
Primary | AUC total (AUC 0-8) | area under the plasma concentration-time curve from zero to infinity. | 0 to 24 hours post dose | |
Secondary | Time to reach maximum plasma concentration | Time required for the drug to reach maximum plasma concentration | up to 24 hours post dose |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05029518 -
3-Way Crossover Study to Compare the PK (Pharmokinetics) and to Evaluate the Effect of Food on the Bioavailability
|
Phase 1 | |
Completed |
NCT05001152 -
Taste Assessment of Ozanimod
|
Phase 1 | |
Completed |
NCT04493255 -
A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants
|
Phase 1 | |
Completed |
NCT03457649 -
IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT00995891 -
Collection of Blood, Bone Marrow, and Buccal Mucosa Samples From Healthy Volunteers for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Laboratory Research Studies
|
||
Completed |
NCT05043766 -
Evaluation of Oral PF614 Relative to OxyContin
|
Phase 1 | |
Completed |
NCT05050318 -
Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively
|
Phase 4 | |
Completed |
NCT04466748 -
A Multiple Ascending Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects
|
Phase 1 | |
Completed |
NCT00746733 -
Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC
|
Phase 1 | |
Recruiting |
NCT05929651 -
Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy
|
Phase 4 | |
Completed |
NCT05954039 -
Evaluation of the Efficacy of a Dietary Supplement on Hair Loss and Hair Aspect
|
N/A | |
Completed |
NCT05045716 -
A Study of Subcutaneous Lecanemab in Healthy Participants
|
Phase 1 | |
Active, not recruiting |
NCT02747927 -
Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children
|
Phase 3 | |
Completed |
NCT05533801 -
A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants
|
Phase 1 | |
Not yet recruiting |
NCT03931369 -
Adaptation of Thirst to a Single Administration of Tolvaptan (TOLVATHIRST)
|
Phase 2 | |
Completed |
NCT03279146 -
A Single Dose Study Evaluating PK of TXL Oral Formulations in Healthy Subjects
|
Phase 1 | |
Completed |
NCT06027437 -
A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants
|
Phase 1 | |
Recruiting |
NCT05619874 -
Effects of Two Virtual HIFCT Programs in Adults With Abdominal Obesity
|
N/A | |
Completed |
NCT05553418 -
Investigational On-body Injector Clinical Study
|
N/A | |
Completed |
NCT04092712 -
Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers
|
Phase 1 |